OMGAQ (Omega Therapeutics) Retained Earnings: $-387.51 Mil (As of Sep. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OMGAQ Omega Therapeutics Inc OMGAQ
16 GF Score
Price $0.00
View Full Analysis

What is Omega Therapeutics Retained Earnings?

Omega Therapeutics OMGAQ +50.00% 16 Retained Earnings is $-387.51 Mil as of Sep. 2024. GuruFocus rates OMGAQ with a GF Score™ of 16/100.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Omega Therapeutics's retained earnings for the quarter that ended in Sep. 2024 was $-387.51 Mil.

Omega Therapeutics's quarterly retained earnings declined from Mar. 2024 ($-354.76 Mil) to Jun. 2024 ($-371.07 Mil) and declined from Jun. 2024 ($-371.07 Mil) to Sep. 2024 ($-387.51 Mil).

Omega Therapeutics's annual retained earnings declined from Dec. 2021 ($-134.51 Mil) to Dec. 2022 ($-237.21 Mil) and declined from Dec. 2022 ($-237.21 Mil) to Dec. 2023 ($-334.63 Mil).


Omega Therapeutics  (OTCPK:OMGAQ) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Omega Therapeutics Retained Earnings Historical Data

* Premium members only.

The historical data trend for Omega Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Omega Therapeutics Retained Earnings Chart

Omega Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
-36.78 -66.23 -134.51 -237.21 -334.63

Omega Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -314.42 -334.63 -354.76 -371.07 -387.51
OMGAQ
16GF Score
Omega Therapeutics Inc OMGAQ
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Omega Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-387.51 Mil mean?
Omega Therapeutics (OMGAQ) has a Retained Earnings of $-387.51 Mil as of Sep. 2024. Retained earnings is the amount of net income not issued to shareholders. View historical data on Omega Therapeutics and its competitors.
Is Omega Therapeutics' Retained Earnings too high?
Omega Therapeutics' current Retained Earnings is $-387.51 Mil. Overall, Omega Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Omega Therapeutics' Retained Earnings compare to ENDV and ORGS?
Omega Therapeutics' Retained Earnings of $-387.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Omega Therapeutics and its competitors. Omega Therapeutics's current Retained Earnings is $-387.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omega Therapeutics stock overvalued right now?
Omega Therapeutics (OMGAQ) has a current Retained Earnings of $-387.51 Mil. The current Retained Earnings is $-387.51 Mil. Omega Therapeutics' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Omega Therapeutics (OMGAQ), the current Retained Earnings is $-387.51 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Omega Therapeutics Business Description

Address 140 First Street, Suite 501, Cambridge, MA, USA, 02141
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.
16GF Score

Get the complete analysis for OMGAQ

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price